Abstract
Atrial fibrillation (AF) and heart failure are the two modern epidemics of cardiovascular disease. They are commonly encountered together and either condition predisposes to the other. Patients with both AF and heart failure carry a poor prognosis; therefore, the management of this group of patients should be addressed aggressively. In the context of AF management in patients with heart failure, the pharmacologic rhythm control strategy is not superior to the rate control strategy. Due to the adverse effects of anti-arrhythmic agents, the rate control should be considered as a primary approach. The long-term data regarding the efficacy and safety of catheter-based ablation therapy in the patients with heart failure are limited; hence, the catheter ablation of AF should be reserved for the patients whom the drug therapy is inadequate or undesirable. Ultimately, the patient’s symptoms and the tolerance for the particular treatment should be taken into account for the management of AF in the patients with heart failure.
Financial & competing interests disclosure
The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.
No writing assistance was utilized in the production of this manuscript.